Replies to post #223210 on Biotech Values

[kris_kade]

‘Dirt cheap’ ? Bit amused. So only dumb retails seeing this EV thesis ? If this was this cheap, wonder why Dan couldn’t sell the story. Either he is uncompetitive or street doesn’t buy RT002 story. May be both.

Now street will look to see sales ramp before being convinced and that’s an Year and half away especially considering current FDA slow down. Dead money as far as I am concerned.

[jbog]

RVNC sells 6.76M* shares @$17—a 15.8% discount to Tuesday’s close:

The pricing is very bad, probably about a 25% discount to any moving average. Management screwed this one and it might show the new CFO's ability to manage a company.

[biotech jim]

Reloaded RVNC, after a long watchful waiting.

I tried to get $17.32 pre-market, but failed. Never thought I would get that price during normal hours.

Should be interesting. Will we see a bounce off the offering price? Sheesh.

[DewDiligence]

RVNC 4Q18 results—2019 cash-burn guidance=$148-158M*:

https://investors.revance.com/news-releases/news-release-details/revance-releases-fourth-quarter-and-full-year-2018-results

The FDA agreed that the 351(k) pathway is appropriate for the Botox-biosimilar program partnered with MYL.

Guidance for the RT002 BLA submission remains “1H19”.

*RVNC’s 1/31/19 cash was $296M, according to the CC.